-
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $5 at RBC Capital
-
RBC Capital Downgrades Amneal Pharmaceuticals (AMRX) to Sector Perform
-
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $17 at RBC Capital
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $23 at RBC Capital
-
Amneal Pharmaceuticals (AMRX) Top Generic Idea for 2019 - RBC
-
UPDATE: RBC Capital Upgrades Amneal Pharmaceuticals (AMRX) to Outperform; EBITDA Ramp is Beginning
-
Impax Laboratories, LLC Announces Results of Tender Offer for 2.00% Convertible Senior Notes Due 2022

